ZLAB - Why Is Cancer Focused-Novocure's Stock Plunging Today? | Benzinga
Novocure Ltd (NASDAQ: NVCR) shares are falling after the company's phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields (TTFields) together with paclitaxel in patients with platinum-resistant ovarian cancer did not meet its primary endpoint of overall survival (OS) at the final analysis.
Tumor Treating Fields use electric fields to disrupt cell division. These Fields do not stimulate or heat tissue and target dividing cancer cells of a specific size, thus causing minimal ...